People with neuroendocrine tumours (NETs) in the liver could benefit from a therapy that targets tumours with radiation while limiting exposure to healthy surrounding tissue, according to new guidance from the National Institute for Health and Care Excellence (NICE). NETs are cancers of neuroendocrine cells commonly spread from organs such as the gastrointestinal tract or pancreas to the liver. The guidance is significant as it offers another option for healthcare professionals to treat patients within the National Health Service in England and Wales.

Read more here.